China · 
Who invested in Immunocan?
Immunocan's investors include Vivo Capital, Gold Mine Multi Family Office, Kingray Capital and TigerYeah Capital. Vivo Capital led its latest round.
China · Series A startup
Who invested in Immunocan
One round we have observed, with the 4 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Raised 5 months ago
Funding summaryUpdated 26 Oct 2026
Undisclosedraised across 1 round since 2026, from 1 source
- Latest round
- Series AMay 2026
- Led by
- Vivo Capital
- Investors
- 4 (1 led)
The rounds
- May 2026Series ARMB250 million
Reported by TechNode
Everyone who backed them
Gold Mine Multi Family OfficeFamily office1round
Kingray CapitalVC firm1round
TigerYeah CapitalVC firm1round
Missing a round, or an investor who was in one? Tell us.
Quick answers about Immunocan
How much has Immunocan raised?
Immunocan has raised 1 round since 2026, none with a disclosed amount.
When did Immunocan last raise?
Immunocan's most recent round was a Series A in May 2026, led by Vivo Capital.
Who backed Immunocan first?
Immunocan's first round on record, in May 2026, was backed by Vivo Capital, Gold Mine Multi Family Office and Kingray Capital and 1 others.
What stage is Immunocan at?
Immunocan's latest named round is a Series A, in May 2026.
Where is Immunocan based?
Immunocan is based in China.
Who led Immunocan's rounds?
Vivo Capital led the Series A in 2026.
Companies like Immunocan
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.